Observe Medical Gestione

Gestione criteri di controllo 1/4

Observe Medical Il CEO è Jorgen Mann, nominato in Feb2024, ha un mandato di meno di un anno. possiede direttamente 0.2% delle azioni della società, per un valore di € 16.10K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.8 anni e 4.8 anni.

Informazioni chiave

Jorgen Mann

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.2%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Jorgen Mann

less than a year

Mandato

Mr. Jørgen Mann was Chief Commercial Officer of Observe Medical ASA from January 2023 until 2024 and serves as it's Interim Chief Executive Officer since February 2024. He has experience in sales and senio...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rune Nystad	Chief Development Officer	less than a year	NOK 3.11m	0.47% € 36.9k
Jorgen Mann	Interim Chief Executive Officer	less than a year	Nessun dato	0.20% € 16.1k
Johan Fagerli	Interim Chief Financial Officer	less than a year	Nessun dato	0.10% € 8.1k

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di OM5A non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Terje Bakken	Chairman of the Board	5.4yrs	NOK 300.00k	Nessun dato
Kathrine E. Andreassen	Director	5.4yrs	NOK 225.00k	0.35% € 28.0k
Jan van Der Linden	Member of Advisory Board	4.8yrs	Nessun dato	Nessun dato
Anders Ternhag	Member of Advisory Board	4.8yrs	Nessun dato	Nessun dato
Eskild Endrerud	Independent Director	2.4yrs	NOK 255.00k	0.41% € 32.6k
Line Tonnessen	Independent Director	2.4yrs	NOK 265.00k	0.38% € 30.0k

4.8yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di OM5A sono considerati esperti (durata media dell'incarico 4.8 anni).

Observe Medical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Observe Medical Asa Announces CFO Changes

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Recent updates

First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023)

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Observe Medical Asa Announces CFO Changes

New major risk - Financial position

New minor risk - Financial data availability

New major risk - Shareholder dilution

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

No independent directors

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA Announces Executive Appointments

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: €2.84

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: €1.42

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: €1.24

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: €1.04

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: €1.09

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: €1.16

First half earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media